TEZEPELUMAB EFFECTS ON INFLAMMATORY BIOMARKERS IN PATIENTS WITH SEVERE, UNCONTROLLED ASTHMA BY BASELINE BIOMARKER LEVEL
Lugogo N, Chupp G, Corren J, Israel E, Molfino N, Martin N, Spahn J, Ambrose C. TEZEPELUMAB EFFECTS ON INFLAMMATORY BIOMARKERS IN PATIENTS WITH SEVERE, UNCONTROLLED ASTHMA BY BASELINE BIOMARKER LEVEL. Annals Of Allergy Asthma & Immunology 2024, 133: s53-s54. DOI: 10.1016/j.anai.2024.08.184.Peer-Reviewed Original ResearchInflammatory biomarker levelsBaseline biomarker levelsBiomarker levelsPost hoc pooled analysisEffect of tezepelumabBaseline to weekLevels of FeNOSerum total IgESerum total IgE.Absolute percentage changeIncreased levelsDouble-blindPlacebo-controlledTezepelumabTotal IgEInflammatory biomarkersParallel-groupUncontrolled asthmaFeNOPatientsPercentage changeBiomarkersPlaceboWeeksBaselineEfficacy of Tezepelumab in Patients with Severe, Uncontrolled Asthma Across Multiple Clinically Relevant Subgroups in the NAVIGATOR Study
Carr T, Moore W, Kraft M, Brusselle G, Castro M, Chupp G, Wechsler M, Hunter G, Lindsley A, Llanos J, Burke L, Chandarana S, Ambrose C. Efficacy of Tezepelumab in Patients with Severe, Uncontrolled Asthma Across Multiple Clinically Relevant Subgroups in the NAVIGATOR Study. Advances In Therapy 2024, 41: 2978-2990. PMID: 38802635, PMCID: PMC11213736, DOI: 10.1007/s12325-024-02889-8.Peer-Reviewed Original ResearchAnnualized asthma exacerbation rateClinically relevant subgroupsEfficacy of tezepelumabBaseline patient characteristicsUncontrolled asthmaClinically relevant subgroups of patientsPatient characteristicsStandard-of-care therapyRelevant subgroups of patientsTezepelumab reduced exacerbationsRelevant subgroupsPlacebo-controlled studyAsthma exacerbation rateSubgroup of patientsReducing asthma exacerbationsBody mass indexPost hoc analysisNSAID sensitivityDouble-blindExacerbation rateTezepelumabSmoking historyPatient subgroupsPlaceboIntroductionMany patients